Human histocompatibility leukocyte antigen (HLA)-DM is a facilitator of antigen presentation via major histocompatibility complex (MHC) class II molecules. In the absence of HLA-DM, MHC class II molecules do not present natural peptides, but tend to remain associated with class II-associated invariant chain peptides (CLIP). Recently, DM was shown to catalyze the release of CLIP from HLA-DR. We have investigated which peptides bound to HLA-DR are vulnerable to release upon encountering DM. By directed substitution of allele-specific anchor residues between CLIP and DR3-cognate peptides and the application of recombinant DM we show that DM catalyzes the release of those peptides bound to HLA-DR3 that do not have appropriate anchor residues and, hence, no optimal ligand binding motif. Thus, HLA-DM acts as a peptide editor, facilitating selection of peptides that stably bind to class II molecules for eventual presentation to the immune system from the pool of available peptides.
Article|
November 01 1996
Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs.
S M van Ham,
S M van Ham
Human Immunogenetics Laboratory, Imperial Cancer Research Fund, Holborn, London, United Kingdom.
Search for other works by this author on:
U Grüneberg,
U Grüneberg
Human Immunogenetics Laboratory, Imperial Cancer Research Fund, Holborn, London, United Kingdom.
Search for other works by this author on:
G Malcherek,
G Malcherek
Human Immunogenetics Laboratory, Imperial Cancer Research Fund, Holborn, London, United Kingdom.
Search for other works by this author on:
I Bröker,
I Bröker
Human Immunogenetics Laboratory, Imperial Cancer Research Fund, Holborn, London, United Kingdom.
Search for other works by this author on:
A Melms,
A Melms
Human Immunogenetics Laboratory, Imperial Cancer Research Fund, Holborn, London, United Kingdom.
Search for other works by this author on:
J Trowsdale
J Trowsdale
Human Immunogenetics Laboratory, Imperial Cancer Research Fund, Holborn, London, United Kingdom.
Search for other works by this author on:
S M van Ham
Human Immunogenetics Laboratory, Imperial Cancer Research Fund, Holborn, London, United Kingdom.
U Grüneberg
Human Immunogenetics Laboratory, Imperial Cancer Research Fund, Holborn, London, United Kingdom.
G Malcherek
Human Immunogenetics Laboratory, Imperial Cancer Research Fund, Holborn, London, United Kingdom.
I Bröker
Human Immunogenetics Laboratory, Imperial Cancer Research Fund, Holborn, London, United Kingdom.
A Melms
Human Immunogenetics Laboratory, Imperial Cancer Research Fund, Holborn, London, United Kingdom.
J Trowsdale
Human Immunogenetics Laboratory, Imperial Cancer Research Fund, Holborn, London, United Kingdom.
Online ISSN: 1540-9538
Print ISSN: 0022-1007
J Exp Med (1996) 184 (5): 2019–2024.
Citation
S M van Ham, U Grüneberg, G Malcherek, I Bröker, A Melms, J Trowsdale; Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs.. J Exp Med 1 November 1996; 184 (5): 2019–2024. doi: https://doi.org/10.1084/jem.184.5.2019
Download citation file: